Gain Therapeutics (GANX) Enterprise Value (2021 - 2026)

Gain Therapeutics has reported Enterprise Value for 6 years, with the latest figure at $74.9 million in Q2 2026.

• On a quarterly basis, Enterprise Value rose 53.8% year-over-year to $74.9 million in Q2 2026; TTM through Jun 2026 was $74.9 million, a 53.8% increase from a year earlier, with the FY2025 full-year figure at $85.3 million, up 76.94% from the prior year.
• Enterprise Value was $74.9 million for Q2 2026 at Gain Therapeutics, up from $65.9 million in the prior quarter.
• The five-year high for Enterprise Value was $85.3 million in Q4 2025, with the low at $7.7 million in Q2 2024.
• Average Enterprise Value over 5 years is $40.2 million, with a median of $40.4 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Enterprise Value tumbled 87.31% in 2022, then soared 535.65% in 2025.
• Over 5 years, Enterprise Value stood at $17.1 million in 2022, then jumped by 50.6% to $25.7 million in 2023, then soared by 87.72% to $48.2 million in 2024, then surged by 76.94% to $85.3 million in 2025, then declined by 12.24% to $74.9 million in 2026.
• The last three Enterprise Value figures came in at $74.9 million (Q2 2026), $65.9 million (Q1 2026), and $85.3 million (Q4 2025), per Business Quant data.